We thank Dr Rosales for his interest in our article 1 and we thank the editor for the opportunity to respond to the comments. As Dr Rosales correctly states, the RBP/TTR index was developed as a marker of vitamin A status, and not as a prognostic indicator. We demonstrated that the RBP/TTR index is not only a marker of vitamin A status, but is also a prognostic indicator in ELBW infants, thereby correlating vitamin A status to prognosis in these vulnerable infants.
distribution of CRP in this population, with values <1 mg/l in most infants with normal outcome, and much higher values in infants who died or developed BPD, is of clinical relevance. We had used the CRP LL Nanorid kit, which is a low-measuring radial immunodiffusion (RID) kit (which measures down to 0.5 mg/l), and not the CRP EL Nanorid kit (which measures down to 5.2 mg/l). Both the LL and EL RID kits were available from the Binding Site during the time we performed the study, although only the EL kit is currently listed on their website (www.bindingsite.com), as the LL kit is no longer available. As very low concentrations were measured using the high sensitivity assay, the 'spectrum bias' is not due to the inability to measure very low concentrations or extrapolations outside the reference concentrations. We are now measuring CRP using a very high sensitivity ELISA, 2 which can measure CRP concentrations down to 20 ng/ml (20 mg/l) sera.
